<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01049464</url>
  </required_header>
  <id_info>
    <org_study_id>Si628/2009</org_study_id>
    <nct_id>NCT01049464</nct_id>
  </id_info>
  <brief_title>Magnesium Sulphate for Treatment of New Onset Atrial Fibrillation in Medical Intensive Care Unit Patient</brief_title>
  <acronym>EMSAF</acronym>
  <official_title>Efficacy of Magnesium Sulphate for Rate and Rhythm Control of New-onset Atrial Fibrillation in the Medical Critically Ill Patients: A Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of Magnesium sulphate for the rate and
      rhythm control of the new onset (within 48 hours) atrial fibrillation in the hemodynamically
      unstable patients, admitted in the medical intensive care unit patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Atrial fibrillation is one of the most common arrhythmia, reported in the hemodynamically
      unstable patients in the intensive care unit. Loss of atrial contraction and the sequential
      atrioventricular contraction decrease the overall cardiac output which results in severe
      inadequate tissue perfusion. Medications aim for rate and rhythm control are recommended to
      treat new onset atrial fibrillation. These drugs (verapamil, diltiazem, amiodarone and beta
      blockers) may further compromise the patients' cardiac output by its' negative inotropic
      effect.

      Magnesium sulphate with the cell membrane threshold potential stabilizing effect has been
      reported as an effective drug for rate and rhythm control for post-operative atrial
      fibrillation and the atrial fibrillation presented in the hospital emergency unit. However,
      there was inadequate data about the efficacy of Magnesium sulphate for treatment of new onset
      atrial fibrillation in the hemodynamically unstable patients admitted in the medical
      intensive care unit.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of conversion to sinus rhythm and/or ventricular rate less than 120 beats per min</measure>
    <time_frame>6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure, superior vena cava or mixed venous oxygen saturation, cardiac index, inotropic and vasopressors dosage</measure>
    <time_frame>6 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>5%D/W</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients in this group will receive 5%D/W 20 ml intravenous in 10 min and then 5%D/W 100 ml infusion in 6 hours as the placebo drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium sulphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in this group will receive 2g of Magnesium sulphate diluted with 5%D/W into 20 ml solution, infusion intravenously in 10 min then 6g of Magnesium sulphate diluted with 5%D/W into 100 ml solution, infusion intravenously in 6 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.</description>
    <arm_group_label>5%D/W</arm_group_label>
    <other_name>5%D/W</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulphate</intervention_name>
    <description>Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.</description>
    <arm_group_label>Magnesium sulphate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted in medical intensive care unit

          -  Age 18 years or more

          -  New onset atrial fibrillation (within 48 hours), persist for at least 1 hour,
             ventricular rate 120 beats per min or more without evidence of volume depletion (CVP 8
             mmHg or more or receive volume resuscitation about 20-30 ml/kg), oxygen saturation not
             less than 90%, serum Potassium level between 3.0-5.0 mEq/l, serum Calcium level
             between 8.0-11.0 mg/dl

        Exclusion Criteria:

          -  Chronic atrial fibrillation

          -  Severe valvular heart disease including severe mitral regurgitation, mitral stenosis,
             aortic regurgitation, aortic stenosis, tricuspid regurgitation, tricuspid stenosis,
             pulmonic regurgitation or pulmonic stenosis

          -  Indicated for electrical cardioversion

          -  Severe hypomagnesemia (serum Magnesium &lt; 1.2 mg/dl)

          -  Severe hypermagnesemia (serum Magnesium &gt; 5.0 mg/dl)

          -  Renal insufficiency with creatinine &gt; 3.0 mg/dl without renal replacement therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Surat Tongyoo, MD</last_name>
    <phone>6624198534</phone>
    <email>surat_Ty@yahoo.co.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine, Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Surat Tongyoo, MD</last_name>
      <phone>6624198534</phone>
      <email>surat_Ty@yahoo.co.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Surat Tongyoo</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Hemodynamically unstable patients</keyword>
  <keyword>Magnesium sulfate</keyword>
  <keyword>Septic shock</keyword>
  <keyword>Medical intensive care unit</keyword>
  <keyword>New onset atrial fibrillation</keyword>
  <keyword>Critically ill patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

